OpGen (NASDAQ:OPGN) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com started coverage on shares of OpGen (NASDAQ:OPGN) in a note issued to investors on Tuesday. The firm set a “sell” rating on the medical research company’s stock.

OpGen Price Performance

Shares of NASDAQ OPGN opened at $4.89 on Tuesday. The firm has a fifty day moving average of $4.01 and a 200 day moving average of $2.17. OpGen has a one year low of $0.53 and a one year high of $5.25.

About OpGen

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.